Analysis of HER2 expression and gene amplification in adenocarcinoma of the stomach and the gastro-oesophageal junction: Rationale for the Belgian way of working

Acta Gastro-Enterologica Belgica

Volumn 75, Issue 1, 2012, Pages 9-13

  Jouret Mourin, A ^a   Hoorens, A ^b   de Hertogh, G ^c   Vanderveken, J ^a   Demetter, P ^d   van Cutsem, E ^c  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d ERASME HOSPITAL   (Belgium)

Author keywords

Cancer; Gastric cancer; Gastro oesophageal junction; Her2 testing; Immunohistochemistry; In situ hybridisation; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ARTICLE; BELGIUM; CANCER CHEMOTHERAPY; ESOPHAGEAL ADENOCARCINOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH ADENOCARCINOMA;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ESOPHAGOGASTRIC JUNCTION; GENE AMPLIFICATION; HUMANS; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84858690937     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. KOEPPEN H.K., WRIGHT B.D., BURT A.D.M., DYBDAL N.O., SLIWKOWSKI M.X., HILLAN K.J. Overexpresssion of Her2/neu in solid tumours: an immunohistochemical survey. Histopathology, 2001, 38: 96-104.
2. SLAMON D., CLARCK G., WONG S., LEVIN W., ULRICH A., MC GUIRE W. Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science, 1987, 235: 177-182.
3. REVILLION F., BONNETERRE J., PEYRAT J.P. ERBB2 oncogene in human breast cancer and its clinical significance. Eur. J. Cancer, 1998, 34: 791-808.
4. SLAMON D.J., LEYLAND-JONES B., SHAK S., FUCHS H., PATON V., BAJAMONDE A., FLEMING T., EIERMANN W., WOLTER J., PEGRAM M., BASELGA J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med., 2001, 344: 783-792.
5. DOWSETT M., HANNA W.M., KOCKX M., PENAULT-LIORCA F., RÜSCHOFF J., GUTJAHR T., HABBEN K., VAN DE VIJVER M.J. Standardization of HER2 testing: results of an international proficiencytesting ring study. Modern Pathol., 2007, 20: 584-591.
6. JORGENSEN J.T. Targeted HER2 treatment in advanced gastric cancer. Oncology, 2010, 78: 26-33.
7. HOFMANN M., STOSS O, SHI D., BÜTTNER R., VAN DE VIJVER M., KIM W., OCHIAI A., RÜSCHOFF J., HENKEL T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology, 2008, 52: 797-805.
8. RÜSCHOFF J., DIETEL M., BARETTON G., WALCH A., MONGES G., CHENARD M.P., PENAULT-LIORCA F., NAGELMEIER I., SCHLAKE W., HÖFLER H., KREIPE H.H. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch., 2010, 457: 299-307.
9. PARK D.I., YUN J.W., PARK J.H., OH S.J., KIM H.J., CHO Y.K., SOHN C.I., JEON W.K., KIM B.I., YOO C.H., SON B.H., CHO E.Y., CHAE S.W., KIM E.J., SOHN J.H., RYU S.H., SEPULVEDA A.R. HER2 / neu amplification is an independent prognostic factor in gastric cancer. Dig. Dis. Sci., 2006, 51: 1371-1379.
10. GARCIA I., VIZOSO F., MARTIN A., SANZ L., ABDEL-LAH O., RAIGOSO P., GARCIA-MUNIZ J.L. Clinical significance of the EGFR and HER2 receptor in respectable gastric cancer. Ann. Surg. Oncol., 2003, 10: 234-241.
11. BANG Y.J., VAN CUTSEM E., FEYEREISLAVA A., CHUNG H.C., SHEN L., SAWAKI A., LORDICK F., OHTSU A., OMURO Y., SATOH T., APRILE G., KULIKOV E., HILL J., LEHLE M., RÜSCHOFF J., KANG Y.K. for the ToGA Trial investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2 - positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376: 687-697.
12. MARX A.H., THARUN L., MUTH J., DANCAU A.M., SIMON R., YEKEBAS E., KAIFI J., MIRLACHER M., BRÜMMENDORF T., BOKEMEYER C., IZBICHI J., SAUTER G. HER-2 amplification is highly homogenous in gastric cancer. Hum. Pathol., 2009, 10: 739-777.
13. BARROS-SILVA J.D., LEITA D., AFONSO L., VIERA J., DINISRIBEIRO M., FRAGOSO M., BENTO MJ., SANTOS L., FERREIRA P., RÊGO S., BRANDAO C., CARNEIRO F., LOPES C., SCHMITT F., TEIXEIRA M.R. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br. J. Cancer, 2009, 100: 487-493.
14. BANG Y., CHUNG H., XU J., LORDICK F., SAWAKI A., AL-SAKAFF N., LIPATOV O., SEE C., RÜSCHOFF J., VAN CUTSEM E. pathological features of advanced gastric cancer: relationship to HER2 positivity in the global screening programme of the ToGA trial. J. Clin. Oncol., 2009, 27: 15s (suppl; abstr 4556).
15. PENAULT-LLORCA F., CHENARD M.P., BOUCHÉ O.F., METGES J.P., ANDRE T., MONGES G. HER2 and gastric cancer. Recommendations for clinical practice in 2011 Ann. Pathol., 2011, 31: 78-87.
16. BILOUS M., OSAMURA R., RÜSSCHOFF J., VAN DE VIJVER M., HANNA W., PENAUT-LIORCA F., ROCHE P. HER2 amplification is highly homogenous in gastric cancer-letter to the editor. Hum. Pathol., 2009, 41: 304-305.
17. GARCIA-GARCIA E. GOMEZ-MARTIN C., ANGULO B., CONDE E., SUAREZ-GAUTHIER A., ADRADOS M., PERNA C.L., HIDALGO M. LOPEZ-RIOS F. Hybridization for HER2 testing in gastric carcinoma: a comparaison of Fish with a noval fully automated dual colour SISH method. Histopathology, 2011, 59: 8-17.
18. EMEA European Medecines Agency: Opinion 2009 www.emea.europa.eu/pdfs/human/opinion/Herceptin_82246709en.pdf
19. JOURET-MOURIN A., HOORENS A., KOCX M., DEMETTER P., VAN CUTSEM E. Belgian guidelines for Her2 testing in gastric cancer. Belg. J. Med. Oncol., 2011, 5: 14-22.
20. GOLDSTEIN N.S., FERKOWICZ M., ODISH E., MANI A., HASTAH F. Minimum formalin fixation time for consistent estrogen receptor immuno-histochemical staining of invasive breast carcinoma. Am. J. Clin. Pathol., 2003, 120: 86-92.
21. BOERS J.E., MEEUWISSEN H., METHORST N. HER2 status in gastrooesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3, 4B5) and two ISH methods (FISH and SISH). Histopathology, 2011, 58: 383-394.
22. BOZETTI C., NEGRI F.V., LAGRASTA C.A., CRAFA P., BASSANO C., TAMAGNI I., GARDINI G., NIZZOLI R., LEORNARDI F., GASPARRO D., CAMISA R., SILINI E.M., ARDIZZONI A. Comparaison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br. J. Cancer, 2011, 26: 1372-1376.